Researchers announced today that an Alzheimer’s clinical trial spearheaded by Washington University School of Medicine in St. Louis has been cancelled. Initial data analysis showed the drugs being tested, solanezumab and gantenerumab, did not reduce memory loss or cognitive decline in Alzheimer’s.
The phase 2/3 trial was being conducted at 24 different sites across several different countries, including the U.S., Australia, Canada, France, Spain and the U.K.
The clinical trial was being held through Washington University’s Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which focuses on people who are at risk of developing Dominantly Inherited Alzheimer’s disease (DIAD). DIAD affects only about one percent of people with Alzheimer’s, but it begins early, developing in patients as early as their 30s or 40s.
Both solanezumab, which was developed by Eli Lilly and Co., and gantenerumab, which was developed by Roche (and its U.S. affiliate, Genentech), were designed to target beta-amyloid buildup in people with DIAD.
Read more from Being Patient.
